An algorithm for managing the failure of external beam radiotherapy in prostate cancer

BJU International

Volumn 100, Issue 3, 2007, Pages 518-527

  Dudderidge, Tim ^a   Payne, Heather ^a   Emberton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Prostate cancer; Radiotherapy failure; Salvage treatment

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTICLE; BLADDER NECK STENOSIS; BRACHYTHERAPY; CANCER STAGING; COMORBIDITY; CONTRAST ENHANCEMENT; CRYOTHERAPY; DATA BASE; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FISTULA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIOFREQUENCY ABLATION; RECTOVESICAL FISTULA; RISK ASSESSMENT; SALVAGE THERAPY; SCINTISCANNING; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

ALGORITHMS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 34547644637     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06999.x     Document Type: Article

References (67)

1. ASTRO. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997 37 : 1035 41
2. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 360 : 103 6
3. Zietman AL, Christodouleas JP, Shipley WU. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. Int J Radiat Oncol Biol Phys 2005 62 : 714 8
4. Thames H, Kuban D, Levy L et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003 57 : 929 43
5. Roach M III, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006 65 : 965 74
6. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000 48 : 355 67
7. Zietman AL, Tibbs MK, Dallow KC et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 1996 40 : 159 62
8. Ray ME, Thames HD, Levy LB et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. International J Radiat Oncol Biol Phys 2006 64 : 1140 50
9. Aref I, Eapen L, Agboola O, Cross P. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol 1998 48 : 203 7
10. The Royal College of Radiologists' Clinical Oncology Information Network. Guidelines on the management of prostate cancer. London : RCR, 1999
11. Kuban D, Thames H, Levy L et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 2005 61 : 409 14
12. Mullerad M, Hricak H, Kuroiwa K et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005 174 : 2158 63
13. Sala E, Eberhardt SC, Akin O et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 2006 238 : 176 83
14. Remzi M, Fong YK, Dobrovits M et al. The Vienna nomogram. validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate. J Urol 2005 174 : 1256 60
15. Brassell SA, Rosner IL, McLeod DG. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol 2005 15 : 163 6
16. Borley N, Fabrin K, Sriprasad S et al. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in 'high-risk' prostate cancer compared to MRI or CT. Scand J Urol Nephrol 2003 37 : 382 6
17. Harisinghani MG, Saksena MA, Hahn PF et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 2006 186 : 144 8
18. Hinkle GH, Burgers JK, Neal CE et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998 83 : 739 47
19. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002 5 : 132 5
20. Lund GO, Winfield HN, Donovan JF, See WA, Loening SA, Williams RD. Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. J Urol 1997 157 : 548 51
21. Jarrard DF, Chodak GW. Prostate cancer staging after radiation utilizing laparoscopic pelvic lymphadenectomy. Urology 1995 46 : 538 41
22. Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer. comparison of the extended and modified techniques. J Urol 1997 158 : 1891 4
23. Corvin S, Schilling D, Eichhorn K et al. Laparoscopic sentinel lymph node dissection - a novel technique for the staging of prostate cancer. Eur Urol 2006 49 : 280 5
24. Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005 173 : 1943 6
25. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006 50 : 272 9
26. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer. a retrospective study of patients at the Royal Marsden Hospital. BJU Int 2003 92 : 685 9
27. Lee AK, Levy LB, Cheung R, Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 2005 63 : 456 62
28. Faria SL, Mahmud S, Souhami L et al. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology 2006 67 : 142 6
29. Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003 97 : 1127 33
30. Parker CC, Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 1998 49 : 103 10
31. Bianco FJ Jr., Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005 62 : 448 53
32. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005 173 : 1156 60
33. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005 23 : 8198 203
34. Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995 153 : 104 10
35. Touma NJ, Izawa JI, Chin JL. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 2005 173 : 373 9
36. Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999 161 : 857 62
37. Sanderson KM, Penson DF, Cai J et al. Salvage radical prostatectomy. quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006 176 : 2025 31
38. Vallancien G, Gupta R, Cathelineau X, Baumert H, Rozet F. Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol 2003 170 : 1838 40
39. Greene GF, Pisters LL, Scott SM, Von Eschenbach AC. Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol 1998 160 : 86 90
40. Izawa JI, Morganstern N, Chan DM, Levy LB, Scott SM, Pisters LL. Incomplete glandular ablation after salvage cryotherapy for recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003 56 : 468 72
41. Izawa JI, Ajam K, McGuire E et al. Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol 2000 164 : 1978 81
42. Izawa JI, Perrotte P, Greene GF et al. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 2001 165 : 867 70
43. Izawa JI, Madsen LT, Scott SM et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002 20 : 2664 71
44. Perrotte P, Litwin MS, McGuire EJ, Scott SM, Von Eschenbach AC, Pisters LL. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999 162 : 398 402
45. Perrotte P, Tran J, McGuire EJ, Pisters LL. Effect of prior therapy on survival after salvage cryotherapy for recurrent prostate cancer. Prostate Cancer Prostatic Dis 1999 2 : S25
46. Pisters LL, Von Eschenbach AC, Scott SM et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997 157 : 921 5
47. Pisters LL, Perrotte P, Scott SM, Greene GF, Von Eschenbach AC. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 1999 17 : 2514 20
48. Robinson JW, Donnelly BJ, Coupland K et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol 2006 24 : 472 86
49. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001 165 : 1937 41
50. Ismail M, Ahmed S, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007 100 : in press
51. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006 97 : 56 61
52. Uchida T, Baba S, Irie A et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyokika Kiyo 2005 51 : 651 8
53. Uchida T, Sanghvi NT, Gardner TA et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology 2002 59 : 394 8
54. Colombel M, Gelet A. Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis 2004 7 : 289 94
55. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001 40 : 124 9
56. Gelet A, Chapelon JY, Bouvier R et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000 14 : 519 28
57. Thuroff S, Chaussy C, Vallancien G et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003 17 : 673 7
58. Gelet A, Chapelon JY, Poissonnier L et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004 63 : 625 9
59. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999 54 : 880 3
60. Grado GL, Collins JM, Kriegshauser JS et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999 53 : 2 10
61. Wong WW, Buskirk SJ, Schild SE, Prussak KA, Davis BJ. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006 176 : 2020 4
62. Zlotta AR, Djavan B, Matos C et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 1998 81 : 265 75
63. Djavan B, Susani M, Shariat S et al. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. Tech Urol 1998 4 : 103 9
64. Djavan B, Zlotta AR, Susani M et al. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology 1997 50 : 986 92
65. Shariat SF, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 2005 65 : 260 7
66. Gheiler EL, Tefilli MV, Tiguert R et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998 51 : 789 95
67. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005 95 : 751 6